• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将针对阿片类药物使用障碍的X豁免培训纳入执业护士和医师助理课程。

Integrating X-waiver training for opioid use disorder into the nurse practitioner and physician assistant curricula.

作者信息

Moreland Angela D, Durham Catherine O, Rafferty Alyssa, Hartwell Karen J

机构信息

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina.

College of Nursing, Medical University of South Carolina, Charleston, South Carolina.

出版信息

J Am Assoc Nurse Pract. 2025 May 28;37(7):406-412. doi: 10.1097/JXX.0000000000001143. eCollection 2025 Jul 1.

DOI:10.1097/JXX.0000000000001143
PMID:40434339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12226215/
Abstract

Starting in 2016, physician assistants (PAs) and Advanced Practice Registered Nurses could prescribe buprenorphine with an approved waiver, which improves health care through expansion of access to care, reduction of health care costs, and provision of high-quality care. This study addresses barriers to student NP's and PA's ability to prescribe buprenorphine by examining knowledge and attitudes toward prescribing medications for opioid use disorder (MOUD), subjective norms and perceived behavioral control surrounding prescribing MOUD, and the intention to prescribe MOUD among NPs and PAs. Participants were 120 students enrolled in the NP or PA program at 3 large universities in the southeastern United States. Before and after engagement in the 8-hour Waiver Training, participants completed a survey to obtain measures of knowledge, attitudes toward prescribing MOUD, subjective norms, perceived behavioral control, and intention to prescribe MOUD. Results demonstrated increased knowledge regarding MOUD and prescribing practices from pre- to post-training. Students reported being significantly more likely to prescribe buprenorphine, methadone, and naltrexone after completing the waiver training, as well as stronger attitudes that MOUD is beneficial, useful, good, effective, and relevant. Student subjective norms did not significantly change from pre- to post-training, although perceived control significantly increased. Incorporation of training and treatment of patients with MOUD is critical for continued increases in the number of waivered providers.

摘要

从2016年开始,医师助理(PAs)和高级执业注册护士在获得批准的豁免情况下可以开具丁丙诺啡,这通过扩大医疗服务可及性、降低医疗成本以及提供高质量医疗服务来改善医疗保健。本研究通过考察对阿片类药物使用障碍(MOUD)处方用药的知识和态度、围绕MOUD处方的主观规范和感知行为控制,以及NP和PA中MOUD处方的意愿,探讨学生NP和PA开具丁丙诺啡能力的障碍。参与者是美国东南部3所大型大学NP或PA项目的120名学生。在参加8小时的豁免培训前后,参与者完成了一项调查,以获取关于知识、对MOUD处方的态度、主观规范、感知行为控制以及MOUD处方意愿的测量数据。结果表明,从培训前到培训后,关于MOUD和处方实践的知识有所增加。学生报告称,在完成豁免培训后,开具丁丙诺啡、美沙酮和纳曲酮的可能性显著增加,并且对MOUD有益、有用、良好、有效和相关的态度也更强。学生的主观规范从培训前到培训后没有显著变化,尽管感知控制显著增加。将MOUD患者的培训和治疗纳入其中对于获得豁免的提供者数量的持续增加至关重要。

相似文献

1
Integrating X-waiver training for opioid use disorder into the nurse practitioner and physician assistant curricula.将针对阿片类药物使用障碍的X豁免培训纳入执业护士和医师助理课程。
J Am Assoc Nurse Pract. 2025 May 28;37(7):406-412. doi: 10.1097/JXX.0000000000001143. eCollection 2025 Jul 1.
2
Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama.阿拉巴马州阿片类药物使用障碍患者开处丁丙诺啡处方的障碍和机会调查。
J Addict Dis. 2024 Oct-Dec;42(4):410-417. doi: 10.1080/10550887.2023.2247950. Epub 2023 Aug 31.
3
Evaluation of a Multistage Implementation of Medication for Opioid Use Disorder Services in Primary Care.初级保健中阿片类物质使用障碍服务药物治疗多阶段实施情况评估
Subst Use Misuse. 2025;60(9):1308-1318. doi: 10.1080/10826084.2025.2496931. Epub 2025 May 5.
4
Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs.阿片类药物治疗项目中用于阿片类物质使用障碍的药物供应情况。
JAMA Netw Open. 2025 Jun 2;8(6):e2517616. doi: 10.1001/jamanetworkopen.2025.17616.
5
Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.VA 初级保健中阿片类药物使用障碍的药物处方和接受情况:退伍军人和提供者的观点。
J Gen Intern Med. 2024 Jul;39(9):1690-1697. doi: 10.1007/s11606-024-08703-z. Epub 2024 Apr 8.
6
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.州许可的专业物质使用治疗计划中使用丁丙诺啡的障碍和促进因素:对项目领导层的调查。
J Subst Use Addict Treat. 2024 Jul;162:209351. doi: 10.1016/j.josat.2024.209351. Epub 2024 Mar 17.
7
Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type.按种族、民族和保险类型划分的丁丙诺啡和纳曲酮用于阿片类物质使用障碍的情况
JAMA Netw Open. 2025 Jun 2;8(6):e2518493. doi: 10.1001/jamanetworkopen.2025.18493.
8
The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder.阿片类药物使用障碍治疗研究:18 个月阿片类药物使用障碍治疗患者的研究方法和初步结果。
Public Health Rep. 2024 Jul-Aug;139(4):484-493. doi: 10.1177/00333549231222479. Epub 2024 Jan 25.
9
Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder.患者和提供者的药物偏好会影响患有阿片类药物使用障碍的青少年和年轻人的治疗结果。
J Subst Use Addict Treat. 2024 Jul;162:209334. doi: 10.1016/j.josat.2024.209334. Epub 2024 Mar 24.
10
Telemedicine to improve access to medications for opioid use disorder in Illinois, 2022-2024.2022 - 2024年伊利诺伊州通过远程医疗改善阿片类药物使用障碍患者的药物获取情况
Int J Drug Policy. 2025 Mar;137:104729. doi: 10.1016/j.drugpo.2025.104729. Epub 2025 Feb 6.

本文引用的文献

1
Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: An interrupted time series analysis.2021 年 4 月 X 豁免豁免前后丁丙诺啡配药情况:一项中断时间序列分析。
Int J Drug Policy. 2024 Apr;126:104381. doi: 10.1016/j.drugpo.2024.104381. Epub 2024 Mar 8.
2
Medications for opioid use disorder associated with reduced readmissions for patients with severe injection-related infections: A matched cohort study.阿片类药物使用障碍治疗与严重注射相关感染患者再入院减少相关:一项匹配队列研究。
J Subst Use Addict Treat. 2024 May;160:209298. doi: 10.1016/j.josat.2024.209298. Epub 2024 Jan 21.
3
Increasing Primary Care Utilization of Medication-Assisted Treatment (MAT) for Opioid Use Disorder.提高初级保健对阿片类药物使用障碍的药物辅助治疗(MAT)的利用率。
J Am Board Fam Med. 2023 Apr 3;36(2):251-266. doi: 10.3122/jabfm.2022.220281R2. Epub 2023 Mar 22.
4
Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.11 个州医疗补助受助人中阿片类药物使用障碍药物治疗持续时间与过量用药风险的关系:一项回顾性队列研究。
Addiction. 2022 Dec;117(12):3079-3088. doi: 10.1111/add.15959. Epub 2022 Jun 13.
5
Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.《2000 年《药物成瘾治疗法》豁免:开处丁丙诺啡的障碍和促进因素调查及临床医生认知》
JAMA Netw Open. 2022 May 2;5(5):e2212419. doi: 10.1001/jamanetworkopen.2022.12419.
6
Changing Nurse Practitioner Students' Attitudes and Beliefs About Caring for Those With Opioid Use Disorders.改变护士从业者学生对照顾阿片类药物使用障碍患者的态度和信念。
J Addict Nurs. 2021;32(2):115-120. doi: 10.1097/JAN.0000000000000397.
7
Implementation of office-based buprenorphine treatment for opioid use disorder.阿片类物质使用障碍的基于办公室的丁丙诺啡治疗的实施。
J Am Assoc Nurse Pract. 2021 Mar 19;34(1):196-204. doi: 10.1097/JXX.0000000000000588.
8
Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.受保成年人阿片类物质使用障碍的丁丙诺啡治疗质量。
Med Care. 2021 May 1;59(5):393-401. doi: 10.1097/MLR.0000000000001530.
9
Preparing nurse practitioners to combat the opioid epidemic: A survey of nurse practitioner academic programs in the United States.
J Am Assoc Nurse Pract. 2020 Sep 23;33(10):818-823. doi: 10.1097/JXX.0000000000000502.
10
Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.在阿片类药物治疗项目中患者的丙型肝炎病毒(HCV)护理连续性结局和 HCV 社区病毒载量。
J Infect Dis. 2020 Sep 2;222(Suppl 5):S335-S345. doi: 10.1093/infdis/jiz686.